Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy involving benzoyl peroxide, clindamycin, and doxycycline, primarily used in the management of moderate-to-severe acne. Benzoyl peroxide is a topical agent with antibacterial and keratolytic properties that helps keep skin pores clean and reduces the number of acne-causing bacteria. Clindamycin is a topical or systemic antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of bacterial ribosomes, thereby exerting bacteriostatic (and at higher doses, bactericidal) effects against Propionibacterium acnes[1][2][6]. Doxycycline is an oral tetracycline-class antibiotic that also inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit; it has both anti-inflammatory and antimicrobial activity[3][8]. This triple regimen may be used for severe or treatment-resistant cases where monotherapy or dual therapy are insufficient. The combination aims to maximize efficacy while minimizing resistance development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzoyl peroxide + clindamycin + doxycycline.